Lattice Biologics (Lattice Biologics) Cash-to-Debt : N/A (As of Jun. 2021)

View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lattice Biologics's cash to debt ratio for the quarter that ended in Jun. 2021 was N/A.

The historical rank and industry rank for Lattice Biologics's Cash-to-Debt or its related term are showing as below:

LBLTF's Cash-to-Debt is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 2.03
* Ranked among companies with meaningful Cash-to-Debt only.

Lattice Biologics Cash-to-Debt Historical Data

The historical data trend for Lattice Biologics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lattice Biologics Cash-to-Debt Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Cash-to-Debt

Get a 7-Day Free Trial

0.02

0.01

0.02

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash-to-Debt	Get a 7-Day Free Trial															0.01	0.02	0.01	No Debt	N/A

Competitive Comparison of Lattice Biologics's Cash-to-Debt

For the Medical Devices subindustry, Lattice Biologics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lattice Biologics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Cash-to-Debt falls into.

Lattice Biologics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lattice Biologics's Cash to Debt Ratio for the fiscal year that ended in Sep. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.057	/	(2.247	+	0.888)
	=	0.02

Lattice Biologics's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Lattice Biologics (OTCPK:LBLTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lattice Biologics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (Lattice Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines